Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Bristol Myers Squibb Co. closed $10.05 below its 52-week high ($59.46), which the company reached on September 22nd.
What Analysts Are Saying About Bristol-Myers Squibb Stock
In the assessment of 12-month price targets, analysts unveil insights for Bristol-Myers Squibb, presenting an average target of $46.0, a high estimate of $53.00, and a low estimate of $41.00. Witnessing a positive shift, the current average has risen by 0.26% from the previous average price target of $45.88.
Bristol Myers Squibb Dividend Yield Pushes Past 5%
In trading on Monday, shares of Bristol Myers Squibb were yielding above the 5% mark based on its quarterly dividend (annualized to $2.4)
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY shed 1.00% to $49.49 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.03% to 5,634.58 and the Dow Jones Industrial Average DJIA falling 0.04% to 41,606.18. The stock's fall snapped a two-day winning streak.
With 77% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing
Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
FiercePharma
2d
Bristol Myers Squibb axes 79 more in New Jersey as $1.5B cost-reduction program rolls on
The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program. | Bristol Myers ...
insurancebusinessmag
6d
Bristol-Myers faces lawsuit over $2 billion pension risk transfer to Athene
Bristol-Myers Squibb Co is facing a class-action lawsuit related to a $2 billion pension risk transfer deal made five years ...
4d
on MSN
Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
Bristol Myers Squibb & Co (NYSE:BMY) announced new data from the Phase 3 Daybreak trial demonstrating that decreased rates of ...
STAT
8d
Bristol immunotherapy improves responses in lung cancer, setting up Phase 3 study
BARCELONA, Spain — Adding a second immunotherapy from Bristol Myers Squibb to an existing checkpoint inhibitor and ...
FierceBiotech
6d
ESMO: Bristol Myers axes Immatics' bispecific after $150M bet
Bristol Myers Squibb has jettisoned another cancer candidate in-licensed under its former CEO. Immatics is the latest partner ...
Morningstar
2d
Bristol-Myers Squibb Co
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
FiercePharma
8d
ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer field
More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag ...
6d
Evaluating Bristol-Myers Squibb: A Balanced View Amidst NSCLC Treatment Prospects and Market Uncertainties
Analyst Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and keeping the price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
S&P 500 Index
Immatics
Feedback